Emerging pharmacologic treatment options for fragile X syndrome
about
Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X SyndromeWhere Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability DisordersFMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype.Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxietyDelineating the Common Biological Pathways Perturbed by ASD's Genetic Etiology: Lessons from Network-Based StudiesUpdated report on tools to measure outcomes of clinical trials in fragile X syndrome.Fragile X targeted pharmacotherapy: lessons learned and future directions.Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells.Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model.Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome.Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity.Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome.Modeling Fragile X Syndrome in Drosophila.
P2860
Q26739927-3CC1726F-E5DF-4004-B84B-4B1C9CC0A855Q26740071-52E577AC-3E59-43B9-9EA2-94A430EE850DQ30365865-C57A3D7A-9BF9-41E4-99AE-772D7A98F2B4Q30855390-01600420-1638-4457-989B-6C7C82CDE10BQ33624758-328F1836-FC22-41A7-BF6B-1C2092BD73ABQ33785978-E9D1CC7C-6118-4989-90A7-8B27D7E8E370Q33785983-B66CF90C-6870-4A39-A21C-920A412F7328Q36725163-34F6884A-64EA-4AE1-B9A8-7D5CCCA7F405Q37351720-48735179-1EC7-42A8-B8F9-6FA92C6A91F9Q46227616-0D9CCFCE-CA87-4A87-B286-E159DA5A14F9Q47099606-3D5FF29A-4850-4656-A326-49A3B26D1CD7Q47796729-9B633F40-21F0-4798-9F74-23A457999A55Q55119637-9C54C9C3-DA48-437A-836E-352B0B3DDE83
P2860
Emerging pharmacologic treatment options for fragile X syndrome
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Emerging pharmacologic treatment options for fragile X syndrome
@ast
Emerging pharmacologic treatment options for fragile X syndrome
@en
Emerging pharmacologic treatment options for fragile X syndrome
@nl
type
label
Emerging pharmacologic treatment options for fragile X syndrome
@ast
Emerging pharmacologic treatment options for fragile X syndrome
@en
Emerging pharmacologic treatment options for fragile X syndrome
@nl
prefLabel
Emerging pharmacologic treatment options for fragile X syndrome
@ast
Emerging pharmacologic treatment options for fragile X syndrome
@en
Emerging pharmacologic treatment options for fragile X syndrome
@nl
P2093
P2860
P3181
P356
P1476
Emerging pharmacologic treatment options for fragile X syndrome
@en
P2093
Craig A Erickson
Matthew H Davenport
Tori L Schaefer
P2860
P3181
P356
10.2147/TACG.S35673
P407
P577
2015-04-07T00:00:00Z